Nothing Special   »   [go: up one dir, main page]

MX2021010997A - Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1. - Google Patents

Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1.

Info

Publication number
MX2021010997A
MX2021010997A MX2021010997A MX2021010997A MX2021010997A MX 2021010997 A MX2021010997 A MX 2021010997A MX 2021010997 A MX2021010997 A MX 2021010997A MX 2021010997 A MX2021010997 A MX 2021010997A MX 2021010997 A MX2021010997 A MX 2021010997A
Authority
MX
Mexico
Prior art keywords
ctla
combination therapies
blocking agents
cancer combination
blocking agent
Prior art date
Application number
MX2021010997A
Other languages
English (en)
Inventor
Juha Punnonen
Edward Bowman
Drake Laface
David Bauche
Alissa Chackerian
Jeffery Grein
Smita Mauze
Anandi Sawant
Lakshmanan Annamalai
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2021010997A publication Critical patent/MX2021010997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen terapias combinadas contra el cáncer que comprenden un agente bloqueador CTLA-4 y un agente bloqueador PD-1. En términos particulares, se describen terapias combinadas en donde el agente bloqueador CTLA-4 es un anticuerpo anti-CTLA-4 silencioso efector o fragmento de anticuerpo anti-CTLA-4 silencioso efector y el agente bloqueador PD-1 es un anticuerpo anti PD-1 o anti-PD-L1, o fragmento de anticuerpo del mismo.
MX2021010997A 2019-03-13 2020-03-10 Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1. MX2021010997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962817749P 2019-03-13 2019-03-13
PCT/US2020/021783 WO2020185722A2 (en) 2019-03-13 2020-03-10 Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents

Publications (1)

Publication Number Publication Date
MX2021010997A true MX2021010997A (es) 2021-10-01

Family

ID=72426465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010997A MX2021010997A (es) 2019-03-13 2020-03-10 Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1.

Country Status (10)

Country Link
US (1) US20220411507A1 (es)
EP (1) EP3937979A4 (es)
KR (1) KR20210141539A (es)
CN (1) CN113631189A (es)
AU (1) AU2020234785A1 (es)
BR (1) BR112021017892A8 (es)
CA (1) CA3132198A1 (es)
MA (1) MA55316A (es)
MX (1) MX2021010997A (es)
WO (1) WO2020185722A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216478A1 (en) 2020-04-22 2021-10-28 Merck Sharp & Dohme Corp. HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
CA3206241A1 (en) * 2021-01-29 2022-01-28 Guoqing Cao Antigen binding protein and use thereof
JP2024515618A (ja) * 2021-04-14 2024-04-10 アケソ・ファーマシューティカルズ・インコーポレイテッド 抗腫瘍処置における抗体の使用
WO2022222961A1 (zh) * 2021-04-21 2022-10-27 和铂医药(上海)有限责任公司 结合ctla-4的抗体及其用途
KR20230110141A (ko) 2022-01-14 2023-07-21 영남대학교 산학협력단 PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도
US11932693B2 (en) * 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP3760229A3 (en) * 2014-05-15 2021-04-07 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN110505882A (zh) * 2017-03-31 2019-11-26 默沙东公司 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法

Also Published As

Publication number Publication date
KR20210141539A (ko) 2021-11-23
CA3132198A1 (en) 2020-09-17
BR112021017892A2 (es) 2021-12-07
WO2020185722A3 (en) 2020-11-12
AU2020234785A1 (en) 2021-08-19
CN113631189A (zh) 2021-11-09
EP3937979A2 (en) 2022-01-19
US20220411507A1 (en) 2022-12-29
WO2020185722A2 (en) 2020-09-17
MA55316A (fr) 2022-01-19
BR112021017892A8 (pt) 2023-01-31
JP2022525071A (ja) 2022-05-11
EP3937979A4 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
MX2021010997A (es) Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1.
JOP20200003B1 (ar) أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعة
MX2018007613A (es) Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
MX2021009926A (es) Agonistas il-2rbeta-selectivos en combinacion con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
TN2019000159A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
EP3746119A4 (en) METHODS FOR THE TREATMENT OF CANCER OR AN INFECTION USING A COMBINATION OF AN ANTI-PD -1 ANTIBODY, AN ANTI-LAG3 ANTIBODY AND AN ANTI-TIGIT ANTIBODY
EP4386005A3 (en) Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
EP3891187A4 (en) ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF
MX2019012076A (es) Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
NZ734256A (en) Use of plinabulin in combination with immune checkpoint inhibitors
EP3760229A3 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
MX2017012113A (es) Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.
EP3922647A4 (en) ANTI-PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
EP3901172A4 (en) HUMANIZED ANTI-PD-1 ANTIBODIES AND THEIR USE
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
MX2021010119A (es) Tratamiento combinado con anticuerpos anti-cd39 y anticuerpos anti-pd1 o anti-pd-l1.
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
EP4268848A3 (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
MX2021004226A (es) Terapia combinada contra el cáncer.
EP3947447A4 (en) ANTI-CD73, ANTI-PD-L1 ANTIBODIES AND TUMOR TREATMENT CHEMOTHERAPY
CR20230128A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
ZA202309150B (en) Antibody against nkp46 and application of antibody
EP3823991A4 (en) ANTI-PD-1 ANTIBODIES, DOSAGES AND USES THEREOF
NZ768428A (en) Anti-cd137 antibodies for combination with anti-pd-1 antibodies
MX2023003186A (es) Regimenes de dosificacion de anticuerpo anti-ilt4 o su combinacion con anticuerpo anti-pd-1 para el tratamiento de cancer.